Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of KarXT in Bipolar-I Disorder (BALSAM-3)
NCT06929273Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of xanomeline in bipolar I disorder, sponsored by Bristol Myers Squibb. Primary endpoint: Treatment Emergent Adverse Events at 54 weeks. Started Jul 2025; status: recruiting.
02
Drugs
xanomeline
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT06929273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929273.